Loading...

Novel therapies for inflammation

ABCENTRA IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL ANTIBODY THERAPEUTICS FOR INFLAMMATORY DISEASES

Novel Target


Therapeutics that target oxLDL, a novel target and a specific a source of inflammation implicated in cardiovascular disease, rheumatic disease, and cancer.

Enhancing Safety


By targeting oxLDL, safer alternatives to systemic anti-inflammatory treatments may be possible.

Orticumab


Lead candidate, orticumab, is being developed to treat atherosclerosis and plaque psoriasis.

Focused on clinical development of orticumab
for two indications:

Accelerated
Atherosclerosis

Plaque
Psoriasis

Our Grants


Abcentra receives financial support from the European Union’s FP7 grant program Vaccine in Atherosclerosis (VIA)